BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35665848)

  • 1. Microsatellite instability as a marker of prognosis: a systematic review and meta-analysis of endometrioid endometrial cancer survival data.
    Xiao JP; Wang JS; Zhao YY; Du J; Wang YZ
    Arch Gynecol Obstet; 2023 Feb; 307(2):573-582. PubMed ID: 35665848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type.
    Zighelboim I; Goodfellow PJ; Gao F; Gibb RK; Powell MA; Rader JS; Mutch DG
    J Clin Oncol; 2007 May; 25(15):2042-8. PubMed ID: 17513808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microsatellite instability and ploidy status define three categories with distinctive prognostic impact in endometrioid endometrial cancer.
    Bilbao-Sieyro C; Ramírez R; Rodríguez-González G; Falcón O; León L; Torres S; Fernández L; Alonso S; Díaz-Chico N; Perucho M; Díaz-Chico JC
    Oncotarget; 2014 Aug; 5(15):6206-17. PubMed ID: 25026289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG).
    Mackay HJ; Gallinger S; Tsao MS; McLachlin CM; Tu D; Keiser K; Eisenhauer EA; Oza AM
    Eur J Cancer; 2010 May; 46(8):1365-73. PubMed ID: 20304627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microsatellite instability predicts clinical outcome in radiation-treated endometrioid endometrial cancer.
    Bilbao C; Lara PC; Ramírez R; Henríquez-Hernández LA; Rodríguez G; Falcón O; León L; Perucho M; Díaz-Chico BN; Díaz-Chico JC
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):9-13. PubMed ID: 20005452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of CTCF and ZFHX3 Mutation and Associated Outcomes in Endometrial Cancer.
    Walker CJ; Miranda MA; O'Hern MJ; McElroy JP; Coombes KR; Bundschuh R; Cohn DE; Mutch DG; Goodfellow PJ
    J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26330387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Zighelboim I; Ali S; Lankes HA; Backes F; Moore K; Mutch D; Robison K; Behbakht K; Waggoner S; Ghebre RG; Pearl M; Ramirez NC; Goodfellow P
    Gynecol Oncol; 2015 Sep; 138(3):614-9. PubMed ID: 26144601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
    D'Alessandris N; Travaglino A; Santoro A; Arciuolo D; Scaglione G; Raffone A; Inzani F; Zannoni GF
    Gynecol Oncol; 2021 Nov; 163(2):427-432. PubMed ID: 34446267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas.
    Coenegrachts L; Garcia-Dios DA; Depreeuw J; Santacana M; Gatius S; Zikan M; Moerman P; Verbist L; Lambrechts D; Matias-Guiu X; Amant F
    Virchows Arch; 2015 Apr; 466(4):415-22. PubMed ID: 25677978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes.
    Zighelboim I; Schmidt AP; Gao F; Thaker PH; Powell MA; Rader JS; Gibb RK; Mutch DG; Goodfellow PJ
    J Clin Oncol; 2009 Jul; 27(19):3091-6. PubMed ID: 19470935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators.
    An HJ; Kim KI; Kim JY; Shim JY; Kang H; Kim TH; Kim JK; Jeong JK; Lee SY; Kim SJ
    Am J Surg Pathol; 2007 Jun; 31(6):846-53. PubMed ID: 17527071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma.
    Steinbakk A; Malpica A; Slewa A; Skaland I; Gudlaugsson E; Janssen EA; Løvslett K; Fiane B; Kruse AJ; Feng W; Yinhua Y; Baak JP
    Mod Pathol; 2011 Sep; 24(9):1262-71. PubMed ID: 21552210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High frequency microsatellite instability has a prognostic value in endometrial endometrioid adenocarcinoma, but only in FIGO stage 1 cases.
    Steinbakk A; Malpica A; Slewa A; Gudlaugsson E; Janssen EA; Arends M; Kruse AJ; Yinhua Y; Feng W; Baak JP
    Anal Cell Pathol (Amst); 2010; 33(5):245-55. PubMed ID: 21079294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis.
    Jumaah AS; Al-Haddad HS; McAllister KA; Yasseen AA
    PLoS One; 2022; 17(2):e0263585. PubMed ID: 35139130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KLF3 and PAX6 are candidate driver genes in late-stage, MSI-hypermutated endometrioid endometrial carcinomas.
    Rudd ML; Hansen NF; Zhang X; Urick ME; Zhang S; Merino MJ; ; Mullikin JC; Brody LC; Bell DW
    PLoS One; 2022; 17(1):e0251286. PubMed ID: 35081118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis.
    Casanova J; Duarte GS; da Costa AG; Catarino A; Nave M; Antunes T; Serra SS; Dias SS; Abu-Rustum N; Lima J
    Gynecol Oncol; 2024 Mar; 182():99-107. PubMed ID: 38262245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients.
    Bateman NW; Dubil EA; Wang G; Hood BL; Oliver JM; Litzi TA; Gist GD; Mitchell DA; Blanton B; Phippen NT; Tian C; Zahn CM; Cohn DE; Havrilesky LJ; Berchuck A; Shriver CD; Darcy KM; Hamilton CA; Conrads TP; Maxwell GL
    Cancer; 2017 Oct; 123(20):4004-4012. PubMed ID: 28654152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
    Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA
    Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages IA and IB.
    Han KH; Kim HS; Lee M; Chung HH; Song YS
    Medicine (Baltimore); 2017 May; 96(21):e6976. PubMed ID: 28538399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinicopathological characteristics of POLE-mutated/ultramutated endometrial carcinoma and prognostic value of POLE status: a meta-analysis based on 49 articles incorporating 12,120 patients.
    Wu Q; Zhang N; Xie X
    BMC Cancer; 2022 Nov; 22(1):1157. PubMed ID: 36357827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.